Vantive Health
Kidney-care therapeutics, spun off from Baxter in 2024
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Icodextrin (peritoneal ultrafiltration)(Extraneal) | Phase 3 | Peritoneal ultrafiltrationOther | Heart Failure |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.